Lehnert Martin, Weber Daniel G, Taeger Dirk, Raiko Irina, Kollmeier Jens, Stephan-Falkenau Susann, Brüning Thomas, Johnen Georg
Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bürkle-de-la-Camp-Platz 1, 44789, Bochum, Germany.
Clinic for Pneumology, Helios Clinic Emil Von Behring, Walterhöferstr. 11, 14165, Berlin, Germany.
BMC Res Notes. 2020 Jul 29;13(1):359. doi: 10.1186/s13104-020-05187-y.
Calretinin is a well-known immunohistochemical tissue marker in the diagnosis of malignant mesothelioma. Promising results also indicate the use in early detection. In the present cross-sectional survey, correlations of calretinin plasma levels with clinical features were investigated. Plasma samples of 60 patients with malignant pleural mesothelioma (MPM) and 111 cancer-free controls formerly exposed to asbestos were compared. Calretinin concentrations were determined in plasma using an enzyme-linked immunosorbent assay (ELISA).
The median concentration was higher in MPM patients than in controls (0.79 vs. 0.23 ng/ml; p < 0.0001). Patients with epithelioid MPM or biphasic MPM had higher calretinin plasma levels than patients with sarcomatoid MPM. Strong expression of calretinin in the tumor tissue was associated with higher plasma levels. Preoperative patients showed higher levels of calretinin than patients after thoracic surgery (1.20 vs. 0.67 ng/ml; p = 0.096). The suitability of plasma calretinin has been confirmed as a tumor marker in the differential diagnosis of epithelioid MPM. The value of plasma calretinin for therapy monitoring or as a prognostic marker should be further investigated.
钙视网膜蛋白是恶性间皮瘤诊断中一种广为人知的免疫组织化学组织标志物。有前景的结果也表明其可用于早期检测。在本次横断面调查中，研究了血浆钙视网膜蛋白水平与临床特征的相关性。比较了60例恶性胸膜间皮瘤（MPM）患者和111名既往接触过石棉的无癌对照者的血浆样本。使用酶联免疫吸附测定（ELISA）法测定血浆中的钙视网膜蛋白浓度。
MPM患者的中位数浓度高于对照组（0.79对0.23 ng/ml；p < 0.0001）。上皮样MPM或双向性MPM患者的血浆钙视网膜蛋白水平高于肉瘤样MPM患者。肿瘤组织中钙视网膜蛋白的强表达与较高的血浆水平相关。术前患者的钙视网膜蛋白水平高于胸外科手术后的患者（1.20对0.67 ng/ml；p = 0.096）。血浆钙视网膜蛋白作为上皮样MPM鉴别诊断中的肿瘤标志物的适用性已得到证实。血浆钙视网膜蛋白在治疗监测或作为预后标志物方面的价值应进一步研究。
